Abstract library

4 results for "Seitz".
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#900 Renal Effects of Streptozocin: Preliminary Results of the STREPTOTOX Study
Introduction: Based on old studies, Streptozocin (STZ) is known to have some renal toxicity.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Emmanuel Mitry
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS
#1283 Heterotopic Pancreas Mimicking a Gastrointestinal Neuroendocrine Tumor: A Case Report
Introduction: Heterotopic pancreas, defined as an atypical presence of pancreatic tissue with no anatomic or vascular continuity with the pancreas, is relatively rare. In most cases it is diagnosed during autopsy or incidentally, since it becomes symptomatic only in few cases, causing bleeding, pain or obstruction.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: dr Sara Massironi
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.